Marc A Penn, 512883 Sweetspire Cir, Oviedo, FL 32766

7459286, Dec 2, 2008

Oct 22, 2004

10/972058

Stanley L. Hazen - Pepper Pike OH, US
Marc S. Penn - Beachwood OH, US
Renliang Zhang - Beachwood OH, US

The Cleveland Clinic Foundation - Cleveland OH

C12Q 1/28
G01N 33/48

435 28, 426 63

Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine treatment of the patient immediately at presentation in the emergency room.

7776563, Aug 17, 2010

May 23, 2008

12/126109

Stanley L. Hazen - Pepper Pike OH, US
Marc S. Penn - Beachwood OH, US

The Cleveland Clinic Foundation - Cleveland OH

C12Q 1/28

435 28

The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.

7781219, Aug 24, 2010

Dec 6, 2004

11/005563

Stanley L. Hazen - Pepper Pike OH, US
Michael Kinter - Shaker Heights OH, US
Marc S. Penn - Beachwood OH, US
Jonathan Smith - Shaker Heights OH, US
Lemin Zheng - Richmond Heights OH, US

The Cleveland Clinic Foundation - Cleveland OH

G01N 33/53

436 86

Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

7378396, May 27, 2008

Aug 5, 2005

11/198005

Stanley L. Hazen - Pepper Pike OH, US
Marc S. Penn - Beachwood OH, US

The Cleveland Clinic Foundation - Cleveland OH

A61K 38/07
A61K 38/08
A61K 38/10
A61K 38/16

514 14, 514 13, 514 15, 514 16, 514 17, 514 18, 530326, 530327, 530328, 530329, 530330

The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.

8338110, Dec 25, 2012

Mar 23, 2010

12/730137

Stanley L. Hazen - Pepper Pike OH, US
Michael Kinter - Shaker Heights OH, US
Marc S. Penn - Beachwood OH, US
Jonathan Smith - Shaker Heights OH, US
Lemin Zheng - Cleveland OH, US

The Cleveland Clinic Foundation - Cleveland OH

G01N 33/53

435 71, 436518

Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

8349581, Jan 8, 2013

Nov 5, 2008

12/265081

Stanley L. Hazen - Pepper Pike OH, US
Marc S. Penn - Beachwood OH, US
Renliang Zhang - Beachwood OH, US

The Cleveland Clinic Foundation - Cleveland OH

C12Q 1/28
G01N 33/48

435 28, 436 63

Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product.

8445453, May 21, 2013

Jun 21, 2005

11/157603

Marc S. Penn - Beachwood OH, US
Matthew Kiedrowski - Cleveland OH, US

The Cleveland Clinic Foundation - Cleveland OH

A61K 48/00
A01N 63/00

514 44R, 424 931

Chemokines ligands to at least one of CCR1, CCR2, CCR3, or CCR5 can be used to home stem cells for therapeutic applications.

8513007, Aug 20, 2013

Jul 24, 2012

13/556639

Marc S. Penn - Beachwood OH, US
Rahul Aras - Broadview Heights OH, US
Joseph Pastore - Mentor OH, US
Timothy J. Miller - Cleveland Heights OH, US

The Cleveland Clinic Foundation - Cleveland OH
Juventas Therapeutics, Inc. - Cleveland OH

A61K 48/00
C12N 15/00

4353201, 514 44 R

A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.